Benzinga | Nov 11, 2020 05:48AM EST

Cantor Fitzgerald Upgrades Abeona Therapeutics to Overweight, Announces $4 Price Target

Cantor Fitzgerald analyst Kristen Kluska upgrades Abeona Therapeutics (NASDAQ:ABEO) from Neutral to Overweight and announces $4 price target.